



CERTIFICATION OF ENROLLMENT

Study title: Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus

Clinical trials number: 2024-511287-85-00
(hereinafter referred to as "Study")

Promoter/Sponsor: Mirum Pharmaceuticals, Inc
(hereinafter referred to as "Promoter")

The Promoter of the Study here declares that the Centre IRCCS ISMETT screened N°4 patients and enrolled N° 1 patients in 2025.

12-Mar-2026 | 16:07 CET

Date _____

Mike Failly

Name:.....

Signature on behalf of the Promoter _____

Signed by Mike Failly
 *Mike Failly*

I approve this document
12-Mar-2026 | 16:07 CET

602C0E5750EB4E7EAD95F2A1386BA168